Effectiveness of two-dose vaccination with mRNA COVID-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults-Nine States, January-September 2021

Affiliations

¹ Regenstrief Institute, Indianapolis, Indiana, USA.
² Indiana University School of Medicine, Indianapolis, Indiana, USA.
³ Westat, Rockville, Maryland.
⁴ Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon.
⁵ CDC COVID-19 Response Team.
⁶ Baylor Scott & White Health, Texas A&M University College of Medicine, Temple, Texas.
⁷ Department of Biomedical Informatics, Columbia University, New York, New York.
⁸ New York Presbyterian Hospital, New York, New York.
⁹ Division of Infectious Diseases and Clinical Epidemiology, Intermountain Healthcare, Salt Lake City, Utah.
¹⁰ School of Medicine, University of Colorado, Anschutz Medical Campus, Aurora, Colorado.
¹¹ Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California, Oakland, California.
¹² Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana.
¹³ HealthPartners Institute, Minneapolis, Minnesota.
¹⁴ Fairbanks School of Public Health, Indiana University, Indianapolis, Indiana.
¹⁵ Children's Minnesota, Minneapolis, Minnesota.

Peter J Embi et al. Am J Transplant. 2022 Jan.

. 2022 Jan;22(1):306-314.

doi: 10.1111/ajt.16641.

¹ Regenstrief Institute, Indianapolis, Indiana, USA.
² Indiana University School of Medicine, Indianapolis, Indiana, USA.
³ Westat, Rockville, Maryland.
⁴ Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon.
⁵ CDC COVID-19 Response Team.
⁶ Baylor Scott & White Health, Texas A&M University College of Medicine, Temple, Texas.
⁷ Department of Biomedical Informatics, Columbia University, New York, New York.
⁸ New York Presbyterian Hospital, New York, New York.
⁹ Division of Infectious Diseases and Clinical Epidemiology, Intermountain Healthcare, Salt Lake City, Utah.
¹⁰ School of Medicine, University of Colorado, Anschutz Medical Campus, Aurora, Colorado.
¹¹ Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California, Oakland, California.
¹² Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana.
¹³ HealthPartners Institute, Minneapolis, Minnesota.
¹⁴ Fairbanks School of Public Health, Indiana University, Indianapolis, Indiana.
¹⁵ Children's Minnesota, Minneapolis, Minnesota.

No abstract available

References

1. Harpaz R, Dahl RM, Dooling KL. Prevalence of immunosuppression among US adults, 2013. JAMA. 2016;316:2547–2548. doi: 10.1001/jama.2016.16477. - DOI - PubMed
1. Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584:430–436. doi: 10.1038/s41586-020-2521-4. - DOI - PMC - PubMed
1. Deepak P, Kim W, Paley MA, et al. Effect of immunosuppression on the immunogenicity of mRNA vaccines to SARS-CoV-2: a prospective cohort study. Ann Intern Med. 2021. doi:10.7326/M21-1757. PMID: 34461029 - DOI - PMC - PubMed
1. Tenforde MW, Patel MM, Ginde AA, et al. Influenza and other viruses in the acutely Ill (IVY) network. Effectiveness of SARS-CoV-2 mRNA vaccines for preventing COVID-19 hospitalizations in the United States. Clin Infect Dis. 2021. doi:10.1093/cid/ciab687. PMID: 34358310 - DOI
1. CDC . US Department of Health and Human Services, CDC; 2021. COVID-19: Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States. https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-v....